Statement of Advice

elvitegravir 150mg / cobicistat 150mg / emtricitabine 200mg / tenofovir disoproxil (as fumarate) 245mg film-coated tablets (Stribild®)

Gilead Sciences Ltd

12 January 2018

**ADVICE:** in the absence of a submission from the holder of the marketing authorisation

elvitegravir / cobicistat / emtricitabine / tenofovir disoproxil (as fumarate) (Stribild®) is not recommended for use within NHS Scotland.

**Indication under review:** Treatment of HIV-1 infection in adolescents aged 12 to <18 years weighing ≥35kg who are infected with HIV-1 without known mutations associated with resistance to any of the three antiretroviral agents in Stribild® and who have experienced toxicities which preclude the use of other regimens that do not contain tenofovir disoproxil fumarate.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting. As a result we cannot recommend its use within NHSScotland.

**Advice context:**

*No part of this advice may be used without the whole of the advice being quoted in full.*

*This advice represents the view of the Scottish Medicines Consortium. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.*

Chairman
Scottish Medicines Consortium

Published 12 February 2018